NASDAQ · AKBA
Akebia Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AKBA: Nov 05, 2026
Akebia Therapeutics, Inc. Common Stock is expected to report earnings on 11/05/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.03. The reported EPS for the same quarter last year was $0.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.03 | $-0.02 | $-0.04 | 2 |
| Dec 2026 | $-0.04 | $-0.03 | $-0.05 | 2 |
| Mar 2027 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Jun 2027 | $-0.09 | $-0.09 | $-0.09 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks · MarketBeat- Fintel · Oct 23, 5:43 PM EDTAkebia Therapeutics, Inc. Receives Nasdaq Minimum Bid Price Deficiency NoticeOn October 21, 2026, Akebia Therapeutics, Inc. received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market. The notice was issued because, for the last 30 consecutive business days, the bid price for the company's common stock, par value $0.
- RTTNews · Sep 14, 10:51 AM EDTAkebia Doses First Patient In Phase 2 Trial Of Ebribafusp For Rare Kidney Diseases(RTTNews) – Akebia Therapeutics, Inc. (AKBA) announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for rare complement-mediated kidney diseases, including IgA nephropathy (IgAN), lupus nephritis (LN), and C3 glomerulopathy (C3G).
- Fintel · Sep 8, 7:11 PM EDTWestPark Capital Initiates Coverage of Akebia Therapeutics with Buy RatingFintel reports that on September 8, 2026, WestPark Capital initiated coverage of Akebia Therapeutics (NASDAQCM:AKBA) with a Buy recommendation. Akebia Therapeutics, Inc. is a United States-based biopharmaceutical company that focuses on developing and commercializing therapeutics
- Zacks · Aug 5, 6:10 PM EDTAkebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue EstimatesAkebia Therapeutics (AKBA) delivered earnings and revenue surprises of +33.33% and -5.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- MarketBeat · Aug 5, 6:03 PM EDTAkebia Therapeutics Q2 Earnings Call HighlightsAkebia Therapeutics Surges on FDA Approval for Anemia TreatmentAkebia Therapeutics (NASDAQ:AKBA) reported second-quarter revenue growth for its Vafseo anemia treatment while highlighting an interim clinical result from the VOICE study and progress across its kidney disease pipeli
- RTTNews · Aug 3, 11:34 AM EDTAkebia Initiates Phase 2 Trial For Ebribafusp In Kidney Diseases; Initial Data In '27(RTTNews) – Akebia Therapeutics Inc. (AKBA), on Monday reported the initiation of the Phase 2 basket trial evaluating the safety, efficacy, and pharmacokinetics of Ebribafusp in treating rare complement-mediated kidney diseases.
- MarketBeat · Jun 4, 8:05 PM EDTAkebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones NearAkebia Therapeutics Surges on FDA Approval for Anemia TreatmentAkebia Therapeutics (NASDAQ:AKBA) outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside chat at the
- The Motley Fool · May 8, 11:12 AM EDTAkebia (AKBA) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · May 7, 9:22 AM EDTAkebia Therapeutics Q1 Earnings Call HighlightsAkebia Therapeutics Surges on FDA Approval for Anemia TreatmentAkebia Therapeutics (NASDAQ:AKBA) executives highlighted a “strong start” to 2026 on the company’s first-quarter earnings call, pointing to record quarterly net product revenue for its anemia drug Vafseo, expanding us
- Zacks · May 7, 8:50 AM EDTAkebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue EstimatesAkebia Therapeutics (AKBA) delivered earnings and revenue surprises of -125.56% and -5.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 6, 7:45 AM EDTUnited Therapeutics (UTHR) Misses Q1 Earnings and Revenue EstimatesUnited Therapeutics (UTHR) delivered earnings and revenue surprises of -13.58% and -2.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Apr 30, 3:10 PM EDTQ32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?QTTB heads into Q1 earnings with investors eyeing bempikibart updates, as the SIGNAL-AA study progresses with data due in mid-2026.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Akebia Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.